Latest Nutrition News


How to Avoid Unwanted Weight Gain During COVID-19 Pandemic

How to Avoid Unwanted Weight Gain During COVID-19 PandemicSATURDAY, April 18, 2020 (HealthDay News) -- Beware of your fridge, pantry and couch during the coronavirus pandemic. Being cooped up at home with easy access to food can lead to overeating. Couple that with routine housekeeping, working from home, homeschooling your kids and tending to loved ones, and it's a sure-fire recipe for weight gain, experts at the University of Georgia in Athens warn. "These tasks have been added to our many other responsibilities," said Emma Laing, director of dietetics in the College of Family and Consumer Sciences. "So if something has to give as we strive to find our new normal, routines surrounding eating and physical activity might go out the window." To stay on track, get up off the couch. Try to set times during the day for physical activity you...

Juul's Sales Grew Even After Dropping Flavored E-Cigarettes

16 April 2020
Juul`s Sales Grew Even After Dropping Flavored E-CigarettesTHURSDAY, April 16, 2020 (HealthDay News) -- Weeks after e-cigarette giant Juul voluntarily stopped selling many flavored vaping products popular with U.S. teens, sales rebounded as customers switched to varieties still on the shelves. In fact, sales eventually surpassed previous records, according to new American Cancer Society (ACS) research. "When companies are able to make these decisions for themselves, they are theoretically looking out for consumers, but are really making decisions that are good for the company's bottom line, whereas a regulator is able to make a sweeping decision that can serve the interests of public health," said lead researcher Alex Liber, an ACS senior scientist. In 2018, as vaping surged particularly among American teens, the U.S. Food and Drug...

New COVID-19 Test Could Give Results in Under 1 Hour

16 April 2020
New COVID-19 Test Could Give Results in Under 1 HourTHURSDAY, April 16, 2020 (HealthDay News) -- Researchers say they've developed a low-cost swab test that can diagnose COVID-19 infections in about 45 minutes. The CRISPR-based test -- which uses gene-targeting technology and requires no specialized equipment -- could help relieve testing backlogs in the United States as COVID-19 continues to spread, the scientists said. The U.S. Food and Drug Administration has not approved the test, but clinical assessments are being conducted in an effort to fast-track approval. The test is described in a paper published April 16 in the journal Nature Biotechnology. "The introduction and availability of CRISPR technology will accelerate deployment of the next generation of tests to diagnose COVID-19 infection," co-lead developer Dr. Charles Chiu...

Tips for Safe Grocery Shopping

15 April 2020
Tips for Safe Grocery ShoppingWEDNESDAY, April 15, 2020 (HealthDay News) -- You're in lockdown, yet you still have to go grocery shopping, but how do you stay safe and avoid catching the coronavirus? The American Medical Association has some timely tips. When you go to the store: Stay at least six-feet away from other shoppers. Don't shake hands, hug or have any physical contact. Wipe down grocery carts or basket handles with disinfectant wipes if you have them. Don't touch your face. Wear a cloth face mask. While waiting and after leaving the store, use hand sanitizer if you have it. If you're sick, don't go shopping. But if you must, wear a mask, wash your hands often and keep a safe distance between you and others. When you get your groceries home: Although it's unlikely you'll be exposed to...

FDA Approves Koselugo for Pediatric Neurofibromatosis Type 1

14 April 2020
FDA Approves Koselugo for Pediatric Neurofibromatosis Type 1TUESDAY, April 14, 2020 (HealthDay News) -- Koselugo (selumetinib) has received the first approval for treatment of neurofibromatosis type 1 (NF1) in children ages 2 years and older, the U.S. Food and Drug Administration announced Friday. Approved specifically for patients with symptomatic, inoperable plexiform neurofibromas (PNs), Koselugo, a kinase inhibitor, works by blocking a key enzyme to help stop the tumor from growing. The FDA notes that NF1 occurs in one of every 3,000 infants, and 30 to 50 percent of patients born with NF1 develop at least one PN. Approval was based on National Cancer Institute clinical trial data from children with NF1 and an inoperable PN. Fifty children received the recommended dose of 25 mg/m² orally twice a day or until unacceptable adverse reactions...

Copyright © 2018 HealthDay. All rights reserved.